{
  "id": 267750,
  "title": "Better Understanding Of What We Are Really Doing",
  "url": "/competitions/rsna-miccai-brain-tumor-radiogenomic-classification/discussion/267750",
  "author_name": "Darien Schettler",
  "post_date": "2021-08-24T14:41:37.370000",
  "votes": 78,
  "comment_count": 8,
  "views": 0,
  "content": "<p>Hi there, I struggled with this for a bit at the beginning of the competition and am just now getting my head around what we are trying to do (classify) w.r.t. this competition. I figured I would make this discussion post to share my understanding and allow others to comment/clarify as necessary.</p>\n<p><br></p>\n<hr>\n<p><br></p>\n<p><strong>STARTING WITH THE COMPETITION DESCRIPTION</strong></p>\n<blockquote>\n  <p>The presence of a specific genetic sequence in the tumour known as MGMT promoter methylation has been shown to be a favourable prognostic factor and a strong predictor of responsiveness to chemotherapy.</p>\n</blockquote>\n<p><br></p>\n<p><strong>MY INTERPRETATION</strong></p>\n<p>This is a good start. We know we are going to be predicting (<strong>binary classification</strong>) the presence of a genetic sequence (MGMT promoter methylation?) from mpMRI scans of patients with <a href=\"https://www.mayoclinic.org/diseases-conditions/glioblastoma/cdc-20350148#:~:text=Glioblastoma%20is%20an%20aggressive%20type%20of%20cancer%20that%20can%20occur,%2C%20nausea%2C%20vomiting%20and%20seizures.\" target=\"_blank\">gliomas</a>. We can also understand that this classification will help identify if a patient (more specifically their glioma) will respond favourably to chemotherapy.</p>\n<p><br></p>\n<hr>\n<p><br></p>\n<p><strong>NEXT WE LOOK AT A <a href=\"http://www.ajnr.org/content/ajnr/early/2021/03/04/ajnr.A7029.full.pdf\" target=\"_blank\">PAPER ATTEMPTING A SIMILAR TASK</a> AND TARGET THEIR DESCRIPTION</strong></p>\n<blockquote>\n  <p>MGMT is a DNA repair enzyme that protects normal and glioma cells from alkylating chemotherapeutic agents. The methylation of the MGMT promoter is an example of epigenetic silencing, which results in a loss of function of the MGMT enzyme and its protective effect on glioma cells. The survival benefit incurred by MGMT promoter methylation in patients treated with temozolomide (TMZ) was determined in 2005.1 Subsequent work by Stupp et al2 has shown that in patients who received both radiation and temozolomide, MGMT promoter methylation improved median survival compared with patients with unmethylated gliomas (21.7 versus 12.7 months).2 Long-term follow-up from that initial study has further substantiated the survival benefit.2,3As a result, determining MGMT promoter methylation status is an important step in predicting survival and determining treatment.</p>\n</blockquote>\n<p><br></p>\n<p><strong>MY TL;DR UNDERSTANDING</strong></p>\n<ul>\n<li>The MGMT gene (and subsequently the region before this gene known as the promoter) is a thing everyone has. </li>\n<li>This promoter turns on/off the gene that controls the production of an enzyme (transcription) that repairs DNA.</li>\n<li>This enzyme, and consequently the tools that produce it, <em>protect</em> our tissues (DNA), BUT THEY ALSO PROTECT CANCER CELLS, from various things (INCLUDING CHEMOTHERAPY, UNFORTUNATELY).</li>\n<li>When the MGMT promoter (the on/off switch) is methylated it will stop functioning properly (silenced) and will stop producing the protective Enzyme.<ul>\n<li>Since the enzyme created by the MGMT gene is no longer produced… there is no longer any protection for tissues (DNA) or CANCER CELLS. </li></ul></li>\n<li><strong>The methylation/silencing of this promoter region might seem like a bad thing (NO DNA REPAIR = BAD?), but because the enzyme produced by the MGMT gene will ALSO protect the tumour cells from chemotherapeutics, when the MGMT promoter gets methylated (silenced), the chemotherapy can work (hopefully!) as intended and result in successful treatment of the tumour!</strong></li>\n</ul>\n<p><br></p>\n<hr>\n<p><strong>CORRECTION TO THE ABOVE INFORMATION WAS COMPLETED ON AUGUST 27, 2021 TO REFLECT THE COMMENT FROM USER <a href=\"https://www.kaggle.com/ivgona\" target=\"_blank\">@ivgona</a> (thank you!!!)</strong></p>\n<hr>\n<p><br></p>\n<p><strong>SO IN SHORT:</strong> </p>\n<ul>\n<li>WE ARE PREDICTING WHETHER THE MGMT PROMOTER REGION IS METHYLATED.</li>\n<li>THIS SHOULD BE A GOOD <a href=\"https://www.merriam-webster.com/dictionary/prognostic\" target=\"_blank\">PROGNOSTIC</a> INDICATOR FOR TUMOR TREATMENT</li>\n<li><strong>THE PRESENCE OF THIS METHYLATION (AND THE CORRESPONDING ABSENCE OF A MECHANISM TO PRODUCE THE ENZYME CODED FOR BY THE MGMT GENE) WOULD INDICATE THAT THE TUMOR IS MORE LIKELY TO RESPOND POSITIVELY TO CHEMOTHERAPEUTICS!</strong></li>\n</ul>\n<p><br></p>\n<p>So it's essentially binary classification indicating whether or not someone's glioma will have a better chance of responding to chemo just from MRI scans. Very cool!</p>\n<p><br></p>\n<hr>\n<p>I hope this helps! Please don't hesitate to correct or improve my understanding.</p>",
  "messages": [
    {
      "id": 1488861,
      "postDate": "2021-08-24T14:41:37.370Z",
      "content": "<p>Hi there, I struggled with this for a bit at the beginning of the competition and am just now getting my head around what we are trying to do (classify) w.r.t. this competition. I figured I would make this discussion post to share my understanding and allow others to comment/clarify as necessary.</p>\n<p><br></p>\n<hr>\n<p><br></p>\n<p><strong>STARTING WITH THE COMPETITION DESCRIPTION</strong></p>\n<blockquote>\n  <p>The presence of a specific genetic sequence in the tumour known as MGMT promoter methylation has been shown to be a favourable prognostic factor and a strong predictor of responsiveness to chemotherapy.</p>\n</blockquote>\n<p><br></p>\n<p><strong>MY INTERPRETATION</strong></p>\n<p>This is a good start. We know we are going to be predicting (<strong>binary classification</strong>) the presence of a genetic sequence (MGMT promoter methylation?) from mpMRI scans of patients with <a href=\"https://www.mayoclinic.org/diseases-conditions/glioblastoma/cdc-20350148#:~:text=Glioblastoma%20is%20an%20aggressive%20type%20of%20cancer%20that%20can%20occur,%2C%20nausea%2C%20vomiting%20and%20seizures.\" target=\"_blank\">gliomas</a>. We can also understand that this classification will help identify if a patient (more specifically their glioma) will respond favourably to chemotherapy.</p>\n<p><br></p>\n<hr>\n<p><br></p>\n<p><strong>NEXT WE LOOK AT A <a href=\"http://www.ajnr.org/content/ajnr/early/2021/03/04/ajnr.A7029.full.pdf\" target=\"_blank\">PAPER ATTEMPTING A SIMILAR TASK</a> AND TARGET THEIR DESCRIPTION</strong></p>\n<blockquote>\n  <p>MGMT is a DNA repair enzyme that protects normal and glioma cells from alkylating chemotherapeutic agents. The methylation of the MGMT promoter is an example of epigenetic silencing, which results in a loss of function of the MGMT enzyme and its protective effect on glioma cells. The survival benefit incurred by MGMT promoter methylation in patients treated with temozolomide (TMZ) was determined in 2005.1 Subsequent work by Stupp et al2 has shown that in patients who received both radiation and temozolomide, MGMT promoter methylation improved median survival compared with patients with unmethylated gliomas (21.7 versus 12.7 months).2 Long-term follow-up from that initial study has further substantiated the survival benefit.2,3As a result, determining MGMT promoter methylation status is an important step in predicting survival and determining treatment.</p>\n</blockquote>\n<p><br></p>\n<p><strong>MY TL;DR UNDERSTANDING</strong></p>\n<ul>\n<li>The MGMT gene (and subsequently the region before this gene known as the promoter) is a thing everyone has. </li>\n<li>This promoter turns on/off the gene that controls the production of an enzyme (transcription) that repairs DNA.</li>\n<li>This enzyme, and consequently the tools that produce it, <em>protect</em> our tissues (DNA), BUT THEY ALSO PROTECT CANCER CELLS, from various things (INCLUDING CHEMOTHERAPY, UNFORTUNATELY).</li>\n<li>When the MGMT promoter (the on/off switch) is methylated it will stop functioning properly (silenced) and will stop producing the protective Enzyme.<ul>\n<li>Since the enzyme created by the MGMT gene is no longer produced… there is no longer any protection for tissues (DNA) or CANCER CELLS. </li></ul></li>\n<li><strong>The methylation/silencing of this promoter region might seem like a bad thing (NO DNA REPAIR = BAD?), but because the enzyme produced by the MGMT gene will ALSO protect the tumour cells from chemotherapeutics, when the MGMT promoter gets methylated (silenced), the chemotherapy can work (hopefully!) as intended and result in successful treatment of the tumour!</strong></li>\n</ul>\n<p><br></p>\n<hr>\n<p><strong>CORRECTION TO THE ABOVE INFORMATION WAS COMPLETED ON AUGUST 27, 2021 TO REFLECT THE COMMENT FROM USER <a href=\"https://www.kaggle.com/ivgona\" target=\"_blank\">@ivgona</a> (thank you!!!)</strong></p>\n<hr>\n<p><br></p>\n<p><strong>SO IN SHORT:</strong> </p>\n<ul>\n<li>WE ARE PREDICTING WHETHER THE MGMT PROMOTER REGION IS METHYLATED.</li>\n<li>THIS SHOULD BE A GOOD <a href=\"https://www.merriam-webster.com/dictionary/prognostic\" target=\"_blank\">PROGNOSTIC</a> INDICATOR FOR TUMOR TREATMENT</li>\n<li><strong>THE PRESENCE OF THIS METHYLATION (AND THE CORRESPONDING ABSENCE OF A MECHANISM TO PRODUCE THE ENZYME CODED FOR BY THE MGMT GENE) WOULD INDICATE THAT THE TUMOR IS MORE LIKELY TO RESPOND POSITIVELY TO CHEMOTHERAPEUTICS!</strong></li>\n</ul>\n<p><br></p>\n<p>So it's essentially binary classification indicating whether or not someone's glioma will have a better chance of responding to chemo just from MRI scans. Very cool!</p>\n<p><br></p>\n<hr>\n<p>I hope this helps! Please don't hesitate to correct or improve my understanding.</p>",
      "rawMarkdown": "Hi there, I struggled with this for a bit at the beginning of the competition and am just now getting my head around what we are trying to do (classify) w.r.t. this competition. I figured I would make this discussion post to share my understanding and allow others to comment/clarify as necessary.\n\n<br>\n\n---\n\n<br>\n\n**STARTING WITH THE COMPETITION DESCRIPTION**\n\n> The presence of a specific genetic sequence in the tumour known as MGMT promoter methylation has been shown to be a favourable prognostic factor and a strong predictor of responsiveness to chemotherapy.\n\n<br>\n\n**MY INTERPRETATION**\n\nThis is a good start. We know we are going to be predicting (**binary classification**) the presence of a genetic sequence (MGMT promoter methylation?) from mpMRI scans of patients with [gliomas](https://www.mayoclinic.org/diseases-conditions/glioblastoma/cdc-20350148#:~:text=Glioblastoma%20is%20an%20aggressive%20type%20of%20cancer%20that%20can%20occur,%2C%20nausea%2C%20vomiting%20and%20seizures.). We can also understand that this classification will help identify if a patient (more specifically their glioma) will respond favourably to chemotherapy.\n\n<br>\n\n---\n\n<br>\n\n**NEXT WE LOOK AT A [PAPER ATTEMPTING A SIMILAR TASK](http://www.ajnr.org/content/ajnr/early/2021/03/04/ajnr.A7029.full.pdf) AND TARGET THEIR DESCRIPTION**\n\n> MGMT is a DNA repair enzyme that protects normal and glioma cells from alkylating chemotherapeutic agents. The methylation of the MGMT promoter is an example of epigenetic silencing, which results in a loss of function of the MGMT enzyme and its protective effect on glioma cells. The survival benefit incurred by MGMT promoter methylation in patients treated with temozolomide (TMZ) was determined in 2005.1 Subsequent work by Stupp et al2 has shown that in patients who received both radiation and temozolomide, MGMT promoter methylation improved median survival compared with patients with unmethylated gliomas (21.7 versus 12.7 months).2 Long-term follow-up from that initial study has further substantiated the survival benefit.2,3As a result, determining MGMT promoter methylation status is an important step in predicting survival and determining treatment.\n\n<br>\n\n**MY TL;DR UNDERSTANDING**\n\n* The MGMT gene (and subsequently the region before this gene known as the promoter) is a thing everyone has. \n* This promoter turns on/off the gene that controls the production of an enzyme (transcription) that repairs DNA.\n* This enzyme, and consequently the tools that produce it, *protect* our tissues (DNA), BUT THEY ALSO PROTECT CANCER CELLS, from various things (INCLUDING CHEMOTHERAPY, UNFORTUNATELY).\n* When the MGMT promoter (the on/off switch) is methylated it will stop functioning properly (silenced) and will stop producing the protective Enzyme.\n  * Since the enzyme created by the MGMT gene is no longer produced... there is no longer any protection for tissues (DNA) or CANCER CELLS. \n* **The methylation/silencing of this promoter region might seem like a bad thing (NO DNA REPAIR = BAD?), but because the enzyme produced by the MGMT gene will ALSO protect the tumour cells from chemotherapeutics, when the MGMT promoter gets methylated (silenced), the chemotherapy can work (hopefully!) as intended and result in successful treatment of the tumour!**\n\n<br>\n\n---\n\n**CORRECTION TO THE ABOVE INFORMATION WAS COMPLETED ON AUGUST 27, 2021 TO REFLECT THE COMMENT FROM USER @ivgona (thank you!!!)**\n\n---\n\n<br>\n\n**SO IN SHORT:** \n\n* WE ARE PREDICTING WHETHER THE MGMT PROMOTER REGION IS METHYLATED.\n* THIS SHOULD BE A GOOD [PROGNOSTIC](https://www.merriam-webster.com/dictionary/prognostic) INDICATOR FOR TUMOR TREATMENT\n* **THE PRESENCE OF THIS METHYLATION (AND THE CORRESPONDING ABSENCE OF A MECHANISM TO PRODUCE THE ENZYME CODED FOR BY THE MGMT GENE) WOULD INDICATE THAT THE TUMOR IS MORE LIKELY TO RESPOND POSITIVELY TO CHEMOTHERAPEUTICS!**\n\n<br>\n\nSo it's essentially binary classification indicating whether or not someone's glioma will have a better chance of responding to chemo just from MRI scans. Very cool!\n\n<br>\n\n---\n\nI hope this helps! Please don't hesitate to correct or improve my understanding.",
      "votes": 78
    },
    {
      "id": 1489594,
      "postDate": "2021-08-25T05:47:29.977Z",
      "content": "<p>I would like to comment on your understanding of what is MGMT and the promoter region:</p>\n<blockquote>\n  <p>The MGMT gene promoter is a thing everyone has.</p>\n  <p>This promoter protects tissues (BUT ALSO CANCER CELLS) from various things (INCLUDING CHEMOTHERAPY). </p>\n</blockquote>\n<p>MGMT (O6-Methylguanine-DNA Methyltransferase) is a protein (<a href=\"https://www.frontiersin.org/articles/10.3389/fonc.2019.01547/full\" target=\"_blank\">an enzyme to be precise</a>) that repairs DNA, that's why it protects the cell from mutations.<br>\nOn the other hand, a promoter is a <a href=\"https://www.genome.gov/genetics-glossary/Promoter\" target=\"_blank\">region before the gene</a> that regulates the \"on/off\" of it. It's a signaling region for the RNA polymerase to attach and begin the transcription process.<br>\nTherefore, the <a href=\"https://www.nature.com/scitable/topicpage/the-role-of-methylation-in-gene-expression-1070/\" target=\"_blank\">methylation or \"silencing\"</a> of the promoter means the RNA polymerase doesn't have the signaling to attach to the DNA and the MGMT enzyme won't be produced.</p>",
      "rawMarkdown": "I would like to comment on your understanding of what is MGMT and the promoter region:\n\n> The MGMT gene promoter is a thing everyone has.\n\n> This promoter protects tissues (BUT ALSO CANCER CELLS) from various things (INCLUDING CHEMOTHERAPY). \n\nMGMT (O6-Methylguanine-DNA Methyltransferase) is a protein ([an enzyme to be precise](https://www.frontiersin.org/articles/10.3389/fonc.2019.01547/full)) that repairs DNA, that's why it protects the cell from mutations.\nOn the other hand, a promoter is a [region before the gene](https://www.genome.gov/genetics-glossary/Promoter) that regulates the \"on/off\" of it. It's a signaling region for the RNA polymerase to attach and begin the transcription process.\nTherefore, the [methylation or \"silencing\"](https://www.nature.com/scitable/topicpage/the-role-of-methylation-in-gene-expression-1070/) of the promoter means the RNA polymerase doesn't have the signaling to attach to the DNA and the MGMT enzyme won't be produced.",
      "votes": 8,
      "replies": [
        {
          "id": 1493152,
          "postDate": "2021-08-27T16:55:09.300Z",
          "content": "<p>Thanks for the helpful information! I feel much better about my understanding of the relevant biology. I have updated my main post to reflect your comment and my subsequent learnings.</p>",
          "rawMarkdown": "Thanks for the helpful information! I feel much better about my understanding of the relevant biology. I have updated my main post to reflect your comment and my subsequent learnings.",
          "votes": 1
        }
      ]
    },
    {
      "id": 1489333,
      "postDate": "2021-08-24T22:19:52.457Z",
      "content": "<p>Thanks for sharing. This explanation helped me to understand the competition task in a better way =)</p>",
      "rawMarkdown": "Thanks for sharing. This explanation helped me to understand the competition task in a better way =)",
      "votes": 2
    },
    {
      "id": 1488990,
      "postDate": "2021-08-24T16:17:40.800Z",
      "content": "<p>Thanks for this, Darien! Very clear description of the entire process. I had not realised that MGMT methylation is actually good for the patient, since then they can benefit from chemo.</p>",
      "rawMarkdown": "Thanks for this, Darien! Very clear description of the entire process. I had not realised that MGMT methylation is actually good for the patient, since then they can benefit from chemo.",
      "votes": 2
    },
    {
      "id": 1494545,
      "postDate": "2021-08-28T18:52:49.077Z",
      "content": "<p>methlation seem to work \"suppression\" mainly</p>",
      "rawMarkdown": "methlation seem to work \"suppression\" mainly"
    },
    {
      "id": 1492483,
      "postDate": "2021-08-27T07:50:54.337Z",
      "content": "<p>Yes. It helped to understand better. save my time.</p>",
      "rawMarkdown": "Yes. It helped to understand better. save my time."
    },
    {
      "id": 1497239,
      "postDate": "2021-08-31T04:21:19.150Z",
      "rawMarkdown": "",
      "isDeleted": true
    },
    {
      "id": 1488942,
      "postDate": "2021-08-24T15:48:54.507Z",
      "content": "<p>Needed this, Thanks</p>",
      "rawMarkdown": "Needed this, Thanks",
      "votes": 1
    }
  ],
  "comments": [
    {
      "id": 1489594,
      "author_name": "IvGoNa",
      "author_url": "",
      "post_date": "2021-08-25T05:47:29.977000",
      "content": "<p>I would like to comment on your understanding of what is MGMT and the promoter region:</p>\n<blockquote>\n  <p>The MGMT gene promoter is a thing everyone has.</p>\n  <p>This promoter protects tissues (BUT ALSO CANCER CELLS) from various things (INCLUDING CHEMOTHERAPY). </p>\n</blockquote>\n<p>MGMT (O6-Methylguanine-DNA Methyltransferase) is a protein (<a href=\"https://www.frontiersin.org/articles/10.3389/fonc.2019.01547/full\" target=\"_blank\">an enzyme to be precise</a>) that repairs DNA, that's why it protects the cell from mutations.<br>\nOn the other hand, a promoter is a <a href=\"https://www.genome.gov/genetics-glossary/Promoter\" target=\"_blank\">region before the gene</a> that regulates the \"on/off\" of it. It's a signaling region for the RNA polymerase to attach and begin the transcription process.<br>\nTherefore, the <a href=\"https://www.nature.com/scitable/topicpage/the-role-of-methylation-in-gene-expression-1070/\" target=\"_blank\">methylation or \"silencing\"</a> of the promoter means the RNA polymerase doesn't have the signaling to attach to the DNA and the MGMT enzyme won't be produced.</p>",
      "votes": 8,
      "replies": [
        {
          "id": 1493152,
          "author_name": "Darien Schettler",
          "author_url": "",
          "post_date": "2021-08-27T16:55:09.300000",
          "content": "<p>Thanks for the helpful information! I feel much better about my understanding of the relevant biology. I have updated my main post to reflect your comment and my subsequent learnings.</p>",
          "votes": 1,
          "replies": []
        }
      ]
    },
    {
      "id": 1489333,
      "author_name": "Cinthia Cristina Calchi Kleiner",
      "author_url": "",
      "post_date": "2021-08-24T22:19:52.457000",
      "content": "<p>Thanks for sharing. This explanation helped me to understand the competition task in a better way =)</p>",
      "votes": 2,
      "replies": []
    },
    {
      "id": 1488990,
      "author_name": "Sofia Moschou",
      "author_url": "",
      "post_date": "2021-08-24T16:17:40.800000",
      "content": "<p>Thanks for this, Darien! Very clear description of the entire process. I had not realised that MGMT methylation is actually good for the patient, since then they can benefit from chemo.</p>",
      "votes": 2,
      "replies": []
    },
    {
      "id": 1494545,
      "author_name": "mephiroth",
      "author_url": "",
      "post_date": "2021-08-28T18:52:49.077000",
      "content": "<p>methlation seem to work \"suppression\" mainly</p>",
      "votes": 0,
      "replies": []
    },
    {
      "id": 1492483,
      "author_name": "Saurav Solanki",
      "author_url": "",
      "post_date": "2021-08-27T07:50:54.337000",
      "content": "<p>Yes. It helped to understand better. save my time.</p>",
      "votes": 0,
      "replies": []
    },
    {
      "id": 1497239,
      "author_name": "",
      "author_url": "",
      "post_date": "2021-08-31T04:21:19.150000",
      "content": "",
      "votes": 0,
      "replies": []
    },
    {
      "id": 1488942,
      "author_name": "DeepUnderstanding",
      "author_url": "",
      "post_date": "2021-08-24T15:48:54.507000",
      "content": "<p>Needed this, Thanks</p>",
      "votes": 1,
      "replies": []
    }
  ],
  "raw_markdown_by_id": {
    "1488861": "Hi there, I struggled with this for a bit at the beginning of the competition and am just now getting my head around what we are trying to do (classify) w.r.t. this competition. I figured I would make this discussion post to share my understanding and allow others to comment/clarify as necessary.\n\n<br>\n\n---\n\n<br>\n\n**STARTING WITH THE COMPETITION DESCRIPTION**\n\n> The presence of a specific genetic sequence in the tumour known as MGMT promoter methylation has been shown to be a favourable prognostic factor and a strong predictor of responsiveness to chemotherapy.\n\n<br>\n\n**MY INTERPRETATION**\n\nThis is a good start. We know we are going to be predicting (**binary classification**) the presence of a genetic sequence (MGMT promoter methylation?) from mpMRI scans of patients with [gliomas](https://www.mayoclinic.org/diseases-conditions/glioblastoma/cdc-20350148#:~:text=Glioblastoma%20is%20an%20aggressive%20type%20of%20cancer%20that%20can%20occur,%2C%20nausea%2C%20vomiting%20and%20seizures.). We can also understand that this classification will help identify if a patient (more specifically their glioma) will respond favourably to chemotherapy.\n\n<br>\n\n---\n\n<br>\n\n**NEXT WE LOOK AT A [PAPER ATTEMPTING A SIMILAR TASK](http://www.ajnr.org/content/ajnr/early/2021/03/04/ajnr.A7029.full.pdf) AND TARGET THEIR DESCRIPTION**\n\n> MGMT is a DNA repair enzyme that protects normal and glioma cells from alkylating chemotherapeutic agents. The methylation of the MGMT promoter is an example of epigenetic silencing, which results in a loss of function of the MGMT enzyme and its protective effect on glioma cells. The survival benefit incurred by MGMT promoter methylation in patients treated with temozolomide (TMZ) was determined in 2005.1 Subsequent work by Stupp et al2 has shown that in patients who received both radiation and temozolomide, MGMT promoter methylation improved median survival compared with patients with unmethylated gliomas (21.7 versus 12.7 months).2 Long-term follow-up from that initial study has further substantiated the survival benefit.2,3As a result, determining MGMT promoter methylation status is an important step in predicting survival and determining treatment.\n\n<br>\n\n**MY TL;DR UNDERSTANDING**\n\n* The MGMT gene (and subsequently the region before this gene known as the promoter) is a thing everyone has. \n* This promoter turns on/off the gene that controls the production of an enzyme (transcription) that repairs DNA.\n* This enzyme, and consequently the tools that produce it, *protect* our tissues (DNA), BUT THEY ALSO PROTECT CANCER CELLS, from various things (INCLUDING CHEMOTHERAPY, UNFORTUNATELY).\n* When the MGMT promoter (the on/off switch) is methylated it will stop functioning properly (silenced) and will stop producing the protective Enzyme.\n  * Since the enzyme created by the MGMT gene is no longer produced... there is no longer any protection for tissues (DNA) or CANCER CELLS. \n* **The methylation/silencing of this promoter region might seem like a bad thing (NO DNA REPAIR = BAD?), but because the enzyme produced by the MGMT gene will ALSO protect the tumour cells from chemotherapeutics, when the MGMT promoter gets methylated (silenced), the chemotherapy can work (hopefully!) as intended and result in successful treatment of the tumour!**\n\n<br>\n\n---\n\n**CORRECTION TO THE ABOVE INFORMATION WAS COMPLETED ON AUGUST 27, 2021 TO REFLECT THE COMMENT FROM USER @ivgona (thank you!!!)**\n\n---\n\n<br>\n\n**SO IN SHORT:** \n\n* WE ARE PREDICTING WHETHER THE MGMT PROMOTER REGION IS METHYLATED.\n* THIS SHOULD BE A GOOD [PROGNOSTIC](https://www.merriam-webster.com/dictionary/prognostic) INDICATOR FOR TUMOR TREATMENT\n* **THE PRESENCE OF THIS METHYLATION (AND THE CORRESPONDING ABSENCE OF A MECHANISM TO PRODUCE THE ENZYME CODED FOR BY THE MGMT GENE) WOULD INDICATE THAT THE TUMOR IS MORE LIKELY TO RESPOND POSITIVELY TO CHEMOTHERAPEUTICS!**\n\n<br>\n\nSo it's essentially binary classification indicating whether or not someone's glioma will have a better chance of responding to chemo just from MRI scans. Very cool!\n\n<br>\n\n---\n\nI hope this helps! Please don't hesitate to correct or improve my understanding.",
    "1489594": "I would like to comment on your understanding of what is MGMT and the promoter region:\n\n> The MGMT gene promoter is a thing everyone has.\n\n> This promoter protects tissues (BUT ALSO CANCER CELLS) from various things (INCLUDING CHEMOTHERAPY). \n\nMGMT (O6-Methylguanine-DNA Methyltransferase) is a protein ([an enzyme to be precise](https://www.frontiersin.org/articles/10.3389/fonc.2019.01547/full)) that repairs DNA, that's why it protects the cell from mutations.\nOn the other hand, a promoter is a [region before the gene](https://www.genome.gov/genetics-glossary/Promoter) that regulates the \"on/off\" of it. It's a signaling region for the RNA polymerase to attach and begin the transcription process.\nTherefore, the [methylation or \"silencing\"](https://www.nature.com/scitable/topicpage/the-role-of-methylation-in-gene-expression-1070/) of the promoter means the RNA polymerase doesn't have the signaling to attach to the DNA and the MGMT enzyme won't be produced.",
    "1489333": "Thanks for sharing. This explanation helped me to understand the competition task in a better way =)",
    "1488990": "Thanks for this, Darien! Very clear description of the entire process. I had not realised that MGMT methylation is actually good for the patient, since then they can benefit from chemo.",
    "1494545": "methlation seem to work \"suppression\" mainly",
    "1492483": "Yes. It helped to understand better. save my time.",
    "1497239": "",
    "1488942": "Needed this, Thanks"
  }
}